
Aethlon Medical Inc (AKA: Bishop Equities Inc) Profile last edited on: 6/6/2024
CAGE: 47A31
UEI: MUNVGHPLRV56
Business Identifier: Removal of disease-causing particles (viral pathogens and tumor-secreted exosomes), from circulatory system Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
11555 Sorrento Valley Road Suite 203
San Diego, CA 92121
San Diego, CA 92121
(619) 941-0360 |
info@aethlonmedical.com |
www.aethlonmedical.com |
Location: Multiple
Congr. District: 50
County: San Diego
Congr. District: 50
County: San Diego
Public Profile
Aethlon Medical, Inc. is a medical technology company focused on products development targeted to diagnosis and treatment of life- and organ threatening diseases. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. Also under development is TauSome - an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
15-19Revenue Range
1.5M-2MVC funded?
YesPublic/Private
Publicly TradedStock Info
NASDAQ : AEMDIP Holdings
20-24Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2019 | 2 | NIH | $1,860,562 | |
Project Title: A Device Prototype for Isolation of Melanoma Exosomes for Diagnostics and Treatment Monitoring | ||||
2018 | 1 | NIH | $298,444 | |
Project Title: The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from the Blood Circulation | ||||
2017 | 1 | NIH | $299,250 | |
Project Title: Device Strategy for Selective Isolation of Oncosomes and Non Malignant Exosomes |
Key People / Management
Charles J Fisher Jr -- Chief Executive Officer and Director
James A Joyce -- Founder, CEO, Sec. & Director
Rodney S Kenley -- President & Director
Lisa M Boswell -- Director, Quality Systems and Regulatory Affairs
Guy F Cipriani -- Sr. VP, Chief Bus. Officer & Director
James B Frakes -- CFO & Senior VP of Finance
Michael Jacobs -- Associate Director of Manufaturing & Product Development
Steven P Larosa -- Chief Medical Officer
Annette Marleau -- Director of Research
Sunil Sawhney -- Head of Clinical Studies
Thomas L Taccini -- Vice President, Manufacturing and Product Development
James A Joyce -- Founder, CEO, Sec. & Director
Rodney S Kenley -- President & Director
Lisa M Boswell -- Director, Quality Systems and Regulatory Affairs
Guy F Cipriani -- Sr. VP, Chief Bus. Officer & Director
James B Frakes -- CFO & Senior VP of Finance
Michael Jacobs -- Associate Director of Manufaturing & Product Development
Steven P Larosa -- Chief Medical Officer
Annette Marleau -- Director of Research
Sunil Sawhney -- Head of Clinical Studies
Thomas L Taccini -- Vice President, Manufacturing and Product Development
Company News
There are no news available.